Paromomycin Sulfate

This chemical does not meet GHS hazard criteria for 93% (53 of 57) of all reports.

Not Classified；Reported as not meeting GHS hazard criteria by 53 of 57 companies (only 7% companies provided GHS information). For more detailed information, please visit ECHA C&L website.

Aggregated GHS information provided per 57 reports by companies from 5 notifications to the ECHA C&L Inventory.；Reported as not meeting GHS hazard criteria per 53 of 57 reports by companies.；There are 4 notifications provided by 4 of 57 reports by companies with hazard statement code(s).；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Drug Induced Liver Injury Rank (DILIrank 2.0)

Paromomycin sulfate

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

◉ Summary of Use during Lactation；No information is available on the clinical use of paromomycin during breastfeeding. Because paromomycin is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants.；◉ Effects in Breastfed Infants；Relevant published information was not found as of the revision date.；◉ Effects on Lactation and Breastmilk；Relevant published information was not found as of the revision date.

PAROMOMYCIN SULFATE

Antiprotozoal [EPC]

Substances that are destructive to protozoans.

Substances that inhibit the growth or reproduction of BACTERIA.